Enzymatic Debridement Market Sales to Top USD 1,549.2 Mn by 2034 | CAGR of 6.5%

Overview

The global enzymatic debridement market was valued at approximately USD 825.3 million in 2023 and is projected to reach nearly USD 1,549.2 million by 2033, expanding at a compound annual growth rate (CAGR) of 6.5% over the forecast period from 2024 to 2033. Enzymatic debridement plays a critical role in wound care by facilitating the removal of necrotic or dead tissue from wounds that fail to heal naturally due to underlying conditions. These include chronic and acute wounds caused by factors such as diabetes, immobility, or trauma. In 2023, chronic wounds accounted for a dominant market share of 73.3%, driven by the growing global prevalence of diabetes, aging populations, and rising cases of pressure and diabetic foot ulcers.

From a product standpoint, collagenase-based solutions led the market with a 56.4% share, owing to their high biocompatibility and effectiveness in wound healing. Collagenase, derived from microbial and animal sources, is widely accepted by the human body and does not typically trigger infections or adverse reactions, making it a preferred treatment option. Based on end-use, hospitals represented the leading segment with 54.3% market share, primarily due to the increased occurrence of hospital-acquired wounds such as pressure ulcers and post-operative complications, particularly among immobile or long-term care patients.

Regionally, North America held the dominant position in the enzymatic debridement market in 2023, generating revenues of USD 392.0 million and accounting for 47.5% of the global share. This is largely supported by the region’s well-established healthcare infrastructure, high awareness of advanced wound care solutions, and a significant elderly population prone to chronic health conditions. The United States and Canada continue to lead in adopting advanced treatment modalities, reinforcing North America’s leadership in this sector.

Key Takeaways

• In 2023, the global enzymatic debridement market generated a revenue of 3 million in 2023, with a CAGR of 6.5%, and is expected to reach USD 1,549.2 million by the year 2033.
• The type held a major share of the market, with the chronic wounds segment taking the lead in 2023 with a market share of 3%.
• By product, the collagenase product accounted for a significant share of 4%, owing to the wide availability and biocompatibility of the product.
• By end-use, the hospital among the other sub-segments held a significant revenue share of the market with 3% of the global enzymatic debridement market.
• The North American region led the market by securing a market share of 5% in 2023 owing to the surging adoption of advanced wound care technology in the region.

➤ Curious about the content? Explore a sample copy of this report – https://market.us/report/enzymatic-debridement-market/free-sample/

Report Scope

Key Market Segments

By Type

• Chronic Wounds
• Diabetic Foot Ulcers
• Pressure Ulcers
• Venous Leg Ulcers
• Acute Wounds
• Burn
• Other Acute Wounds

By Product

• Collagenase Product
• Papain Product
• Others

By End-use

• Hospitals
• Clinics
• Others

Regional Analysis

In 2023, North America emerged as the leading region in the global enzymatic debridement market, generating revenue of approximately USD 392.0 million and accounting for a dominant 47.5% share. This leadership is primarily attributed to the region’s advanced healthcare infrastructure and the strong presence of countries like the United States and Canada, which are global front-runners in delivering high-quality medical services.

The growing number of diabetic and elderly patients, who are more prone to developing chronic wounds such as diabetic foot ulcers and pressure sores, is fueling the adoption of enzymatic debridement therapies. Additionally, the presence of key industry players like ConvaTec, MediWound, and Smith & Nephew enhances the region’s market growth through continuous product development and innovation in advanced wound care solutions.

➤ Directly purchase a copy of the report – https://market.us/purchase-report/?report_id=21253

Recent Developments

Advancis Medical has introduced AdvaGel and AdvaGel Ag, hydrocolloid dressings designed to enhance wound healing by maintaining a moist environment and facilitating autolytic debridement. These products are engineered to minimize wound shrinkage, ensuring better surface contact and reducing the risk of bacterial growth. The company has also launched AdvaGel Ag, which incorporates silver ions for antimicrobial properties, further promoting optimal healing conditions.

Arobella Medical specializes in low-frequency cavitational ultrasound technology for wound care. Their Qoustic Wound Therapy System™ assists in healing by gently removing dead or diseased tissue cells and bacteria, leaving healthy and pre-healing granulation tissue intact. This method offers a safe, cost-effective alternative to painful sharp debridement and other surgical modalities.

B. Braun offers the Prontosan® Debridement Pad, intended to support the soft mechanical debridement of chronic wounds in combination with Prontosan® Wound Irrigation Solution. This product aids in the gentle removal of necrotic tissue, promoting a clean wound bed conducive to healing.

Coloplast provides Purilon® Gel, a hydrogel used for wounds requiring effective and gentle debridement of necrotic tissue, thereby paving the way for optimal wound healing. It is suitable for necrotic and sloughy wounds such as leg ulcers, pressure ulcers, non-infected diabetic foot ulcers, and first and second-degree burns.

ConvaTec’s AQUACEL® EXTRA™ Hydrofiber® dressing is designed to remove dead, damaged, or infected tissue that would otherwise impair the healing of a wound. The dressing is part of their wound debridement product line, aiming to optimize wound management and accelerate healing processes.

DeRoyal offers the Jetox™ ND Jet Lavage Wound Cleansing & Debridement System, which initiates thorough cleansing using compressed air/oxygen combined with a minimal amount of standard sterile solution. This system quickly and efficiently cleans and debrides wounds without the mess and encumbrance of traditional systems, providing a gentle and effective alternative for patients sensitive to other forms of debridement.

EZ Debride provides a single-use, disposable instrument designed for sharp debridement. The instrument features cutting flutes, a flexible neck, a counter-balanced head, and an easy-grip handle, offering both comfort and precision in wound care. It is intended for the mechanical debridement of topical wounds, including partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, and surgical wounds.

Integra LifeSciences offers MediHoney® Wound & Burn Dressing, which contains Active Leptospermum (Manuka) Honey. This dressing addresses many factors that delay healing and helps promote a moist wound environment, facilitating autolytic debridement and supporting the body’s natural healing processes.

Lohmann & Rauscher provides Hydrosorb® Gel, a hydrogel dressing that facilitates autolytic debridement by maintaining a moist wound environment. This product is designed to support the healing of chronic wounds by promoting the body’s natural enzymatic processes to remove necrotic tissue.

Mölnlycke Healthcare offers Mepitel® One, a silicone wound contact layer that facilitates autolytic debridement. By providing a moist wound environment, it supports the body’s natural enzymatic processes to remove necrotic tissue, promoting healing in chronic wounds.

Key Players Analysis

• Advancis Medical
• Arobella Medical, LLC
• Braun Melsungen AG
• Coloplast
• Convatec Inc.
• DeRoyal Industries
• EZ Debride (US).
• Integra Lifesciences
• Lohmann & Rauscher
• Mölnlycke Healthcare
• RLS Global
• Sanara MedTech Inc.
• Smith & Nephew
• SOLASCURE Limited
• Other Key Players

Conclusion

This growth is further supported by advancements in enzymatic formulations, including collagenase and papain-based agents, which enhance the efficacy and safety of wound debridement procedures. The adoption of these enzymatic agents is particularly notable in hospital settings, where they are increasingly incorporated into wound care protocols to promote faster healing and reduce complications.

As the healthcare industry continues to prioritize patient comfort and recovery, enzymatic debridement is poised to play a pivotal role in the management of chronic wounds, offering a non-invasive alternative to traditional surgical methods.

Discuss Your Needs With Our Analyst

Please share your requirements with more details so our analyst can check if they can solve your problem(s)

Request a Sample Download PDF